{"id":"NCT01343277","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma","officialTitle":"A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2015-01","completion":"2016-04","firstPosted":"2011-04-28","resultsPosted":"2016-01-28","lastUpdate":"2016-08-26"},"enrollment":579,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Liposarcoma or Leiomyosarcoma"],"interventions":[{"type":"DRUG","name":"Trabectedin","otherNames":[]},{"type":"DRUG","name":"Dacarbazine","otherNames":[]}],"arms":[{"label":"Trabectedin","type":"EXPERIMENTAL"},{"label":"Dacarbazine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"approximately 3 years 8 months (From Study start date [27 May 2011] up to final analysis data cut-off [05 January 2015]","effectByArm":[{"arm":"Trabectedin","deltaMin":13.73,"sd":null},{"arm":"Dacarbazine","deltaMin":13.14,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":12},"locations":{"siteCount":88,"countries":["United States","Australia","Brazil","New Zealand"]},"refs":{"pmids":["33960681","31173362","30084934","29177975","26371143"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":155,"n":378},"commonTop":["Nausea","Fatigue","Vomiting","Alanine Aminotransferase Increased","Anaemia"]}}